GlaxoSmithKline Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . GlaxoSmithKline PLC ADR
GSK Stock  USD 41.24  0.65  1.60%   
GlaxoSmithKline PLC financial statements provide useful quarterly and yearly information to potential GlaxoSmithKline PLC ADR investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on GlaxoSmithKline PLC financial statements helps investors assess GlaxoSmithKline PLC's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting GlaxoSmithKline PLC's valuation are summarized below:
Gross Profit
19.9 B
Profit Margin
0.1625
Market Capitalization
82.9 B
Enterprise Value Revenue
3.319
Revenue
30.3 B
There are currently one hundred twenty fundamental trends for GlaxoSmithKline PLC ADR that can be evaluated and compared over time across competitors. We recommend to confirm GlaxoSmithKline PLC's regular fundamental drivers against the all of the trends between 2010 and 2024. Market Cap is expected to rise to about 124 B this year. Enterprise Value is expected to rise to about 139.8 B this year

GlaxoSmithKline PLC Total Revenue

19.93 Billion

Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 B, Interest Expense of 502.2 M or Total Revenue of 19.9 B, as well as many exotic indicators such as Price To Sales Ratio of 3.33, Dividend Yield of 0.0181 or PTB Ratio of 9.29. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.
  
This module can also supplement GlaxoSmithKline PLC's financial leverage analysis and stock options assessment as well as various GlaxoSmithKline PLC Technical models . Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

GlaxoSmithKline PLC Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets32.8 B59 B52.4 B
Slightly volatile
Short and Long Term Debt Total11 B18 B18.7 B
Slightly volatile
Other Current Liabilities15 B14.3 B5.3 B
Pretty Stable
Total Current Liabilities11.2 B21.1 B17.5 B
Slightly volatile
Property Plant And Equipment Net7.2 B10 B9.2 B
Slightly volatile
Net Debt8.3 B15.1 B14.5 B
Slightly volatile
Accounts Payable6.2 B3.7 B10.8 B
Slightly volatile
Cash2.7 B2.9 B4.2 B
Very volatile
Non Current Assets Total20.9 B40.4 B36.6 B
Slightly volatile
Cash And Short Term Investments4 B5.2 B4.8 B
Slightly volatile
Common Stock Shares Outstanding2.2 B4.1 B2.5 B
Slightly volatile
Short Term Investments2.4 B2.2 B684 M
Slightly volatile
Liabilities And Stockholders Equity32.8 B59 B52.4 B
Slightly volatile
Non Current Liabilities Total14.3 B25.1 B25.4 B
Slightly volatile
Inventory3 B5.5 B4.6 B
Slightly volatile
Other Stockholder Equity2.9 B3.2 B4.3 B
Pretty Stable
Total Liabilities25.5 B46.2 B42.9 B
Slightly volatile
Property Plant And Equipment Gross21.2 B20.2 B10.8 B
Slightly volatile
Total Current Assets11.9 B18.6 B15.8 B
Slightly volatile
Capital Stock1.3 B1.3 B1.3 B
Slightly volatile
Short Term Debt2.2 B2.8 B3.3 B
Slightly volatile
Common Stock1.3 B1.3 B1.3 B
Slightly volatile
Intangible Assets11.4 B14.8 B15.8 B
Slightly volatile
Other Liabilities14.2 B11.7 B17.8 B
Very volatile
Long Term Debt17.5 B14.2 B18.4 B
Very volatile
Good Will5.3 B6.8 B6 B
Slightly volatile
Other Current Assets533 M561 M4.2 B
Slightly volatile
Property Plant Equipment9.7 B8.7 B11.3 B
Slightly volatile
Other Assets5.4 B7.9 B5.2 B
Slightly volatile
Net Receivables6.5 B7.4 B6.1 B
Slightly volatile
Long Term Investments77.6 B73.9 B34 B
Slightly volatile
Short and Long Term Debt4.3 B2.7 B7.9 B
Slightly volatile
Additional Paid In Capital3.4 B3.5 B3.1 B
Slightly volatile
Long Term Debt Total20.5 B19.6 B17.7 B
Slightly volatile
Capital Surpluse3.5 B4 B3.1 B
Slightly volatile
Net Invested Capital21.1 B30.2 B21.6 B
Slightly volatile
Cash And Equivalents3 B3.4 B3.6 B
Slightly volatile

GlaxoSmithKline PLC Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.2 B2.3 B1.8 B
Slightly volatile
Interest Expense502.2 M775 M725.1 M
Slightly volatile
Total Revenue19.9 B30.3 B26.6 B
Slightly volatile
Gross Profit14.6 B21.3 B18 B
Slightly volatile
Other Operating Expenses15.3 B23.3 B21.5 B
Slightly volatile
Operating Income5 B7 B5.9 B
Pretty Stable
EBIT5.2 B7 B6 B
Pretty Stable
Research Development3 B5.2 B4 B
Slightly volatile
EBITDA6.4 B9.3 B7.8 B
Pretty Stable
Total Operating Expenses10 B14.3 B12.9 B
Slightly volatile
Income Before Tax4.8 B6.1 B5.4 B
Very volatile
Net Income3.4 B4.9 B4.1 B
Pretty Stable
Income Tax Expense1.2 B756 M1 B
Slightly volatile
Selling General Administrative9.8 B9.4 B9.2 B
Slightly volatile
Cost Of Revenue7.7 B9.1 B8.8 B
Slightly volatile
Net Income Applicable To Common Shares14.1 B13.5 B7.1 B
Slightly volatile
Selling And Marketing Expenses317.2 M333.9 M824 M
Slightly volatile
Net Income From Continuing Ops9.4 B6.5 B10.4 B
Very volatile
Tax Provision669.3 M756 M1.3 B
Slightly volatile
Interest Income45.6 M48 M478.3 M
Slightly volatile
Reconciled Depreciation1.7 B1.5 B2 B
Pretty Stable

GlaxoSmithKline PLC Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow3.4 B4 B4.2 B
Slightly volatile
Begin Period Cash Flow2.2 B3.7 B4.2 B
Very volatile
Depreciation1.4 B2.3 B1.8 B
Slightly volatile
Capital Expenditures1.5 B2.3 B1.9 B
Slightly volatile
Total Cash From Operating Activities4.9 B6.3 B6.1 B
Slightly volatile
Net Income4.6 B4.9 B4.4 B
Pretty Stable
End Period Cash Flow2.1 B2.9 B4 B
Pretty Stable
Dividends Paid3.5 B2.2 B3.6 B
Pretty Stable
Stock Based Compensation335.4 M307 M315.3 M
Slightly volatile
Change To Liabilities596.5 M568.1 M269.9 M
Slightly volatile
Issuance Of Capital Stock9.5 M10 M54.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.333.89332.7054
Slightly volatile
Dividend Yield0.01810.0190.0502
Slightly volatile
Days Sales Outstanding95.0289.095782.1072
Pretty Stable
Free Cash Flow Yield0.0390.03390.0558
Very volatile
Operating Cash Flow Per Share1.581.56662.4258
Pretty Stable
Stock Based Compensation To Revenue0.00850.01010.0107
Pretty Stable
EV To Sales2.694.39063.142
Slightly volatile
Free Cash Flow Per Share1.060.98821.6493
Very volatile
ROIC0.290.20190.2038
Pretty Stable
Inventory Turnover2.131.65081.8782
Pretty Stable
Net Income Per Share1.221.21621.6641
Slightly volatile
Days Of Inventory On Hand153221196
Slightly volatile
Payables Turnover2.052.44181.2958
Pretty Stable
Sales General And Administrative To Revenue0.370.30950.3346
Pretty Stable
Research And Ddevelopement To Revenue0.110.17290.1424
Slightly volatile
Cash Per Share1.51.27892.0271
Slightly volatile
POCF Ratio25.6618.600614.2455
Pretty Stable
Interest Coverage8.579.023213.3495
Slightly volatile
Payout Ratio0.820.4561.2102
Very volatile
PFCF Ratio47.4829.4896137
Slightly volatile
Days Payables Outstanding298149415
Pretty Stable
Income Quality0.971.28811.7065
Very volatile
EV To Operating Cash Flow28.1120.976416.7174
Pretty Stable
PE Ratio14.4223.960321.3424
Pretty Stable
Return On Tangible Assets0.210.13170.1497
Slightly volatile
EV To Free Cash Flow52.233.2563148
Slightly volatile
Earnings Yield0.08120.04170.067
Slightly volatile
Intangibles To Total Assets0.220.36570.3781
Pretty Stable
Net Debt To EBITDA0.851.6241.817
Slightly volatile
Current Ratio1.510.88491.0504
Slightly volatile
Receivables Turnover3.44.09674.4483
Slightly volatile
Graham Number7.589.4949.5383
Pretty Stable
Revenue Per Share6.897.484710.8279
Pretty Stable
Interest Debt Per Share3.74.37867.7226
Pretty Stable
Debt To Assets0.220.28760.3352
Very volatile
Enterprise Value Over EBITDA7.914.338211.0231
Slightly volatile
Short Term Coverage Ratios2.262.25671.8693
Slightly volatile
Price Earnings Ratio14.4223.960321.3424
Pretty Stable
Operating Cycle188310226
Slightly volatile
Days Of Payables Outstanding298149415
Pretty Stable
Dividend Payout Ratio0.820.4561.2102
Very volatile
Price To Operating Cash Flows Ratio25.6618.600614.2455
Pretty Stable
Price To Free Cash Flows Ratio47.4829.4896137
Slightly volatile
Pretax Profit Margin0.310.20010.225
Slightly volatile
Ebt Per Ebit1.060.86790.9083
Pretty Stable
Operating Profit Margin0.320.23060.2429
Slightly volatile
Effective Tax Rate0.120.12460.1995
Slightly volatile
Long Term Debt To Capitalization0.350.51470.6433
Very volatile
Total Debt To Capitalization0.420.55970.6827
Very volatile
Return On Capital Employed0.180.18430.1976
Slightly volatile
Ebit Per Revenue0.320.23060.2429
Slightly volatile
Quick Ratio0.80.59740.4811
Pretty Stable
Net Income Per E B T0.560.8120.7233
Very volatile
Cash Ratio0.170.13940.2413
Slightly volatile
Operating Cash Flow Sales Ratio0.160.20930.217
Pretty Stable
Days Of Inventory Outstanding153221196
Slightly volatile
Days Of Sales Outstanding95.0289.095782.1072
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.440.63070.6073
Pretty Stable
Cash Flow Coverage Ratios0.570.37410.3577
Very volatile
Fixed Asset Turnover2.143.04592.8314
Very volatile
Price Cash Flow Ratio25.6618.600614.2455
Pretty Stable
Enterprise Value Multiple7.914.338211.0231
Slightly volatile
Debt Ratio0.220.28760.3352
Very volatile
Cash Flow To Debt Ratio0.570.37410.3577
Very volatile
Price Sales Ratio3.333.89332.7054
Slightly volatile
Return On Assets0.150.08350.0947
Slightly volatile
Asset Turnover0.780.5140.5559
Slightly volatile
Net Profit Margin0.220.16250.1672
Pretty Stable
Gross Profit Margin0.780.70070.6893
Pretty Stable

GlaxoSmithKline PLC Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap124 B118.1 B77.8 B
Slightly volatile
Enterprise Value139.8 B133.2 B92.3 B
Slightly volatile

GlaxoSmithKline Fundamental Market Drivers

Forward Price Earnings10.3199
Cash And Short Term Investments5.2 B

GlaxoSmithKline Upcoming Events

31st of January 2024
Upcoming Quarterly Report
View
24th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
31st of January 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About GlaxoSmithKline PLC Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include GlaxoSmithKline PLC income statement, its balance sheet, and the statement of cash flows. GlaxoSmithKline PLC investors use historical funamental indicators, such as GlaxoSmithKline PLC's revenue or net income, to determine how well the company is positioned to perform in the future. Although GlaxoSmithKline PLC investors may use each financial statement separately, they are all related. The changes in GlaxoSmithKline PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GlaxoSmithKline PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on GlaxoSmithKline PLC Financial Statements. Understanding these patterns can help to make the right decision on long term investment in GlaxoSmithKline PLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue222 M233.1 M
Total Revenue30.3 B19.9 B
Cost Of Revenue9.1 B7.7 B
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.31  0.37 
Research And Ddevelopement To Revenue 0.17  0.11 
Capex To Revenue(0.08)(0.08)
Revenue Per Share 7.48  6.89 
Ebit Per Revenue 0.23  0.32 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
How To Invest In GlaxoSmithKline
Details
Is GlaxoSmithKline Stock a good investment?
Details
What is GlaxoSmithKline PLC's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Dividend Share
0.58
Earnings Share
2.97
Revenue Per Share
14.97
Quarterly Revenue Growth
0.092
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY